Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

Kilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, Marnix Geukes Foppen, Jianda Yuan, Michael A. Postow, Phillip Wong, Emanuela Romano, Amir Khammari, Brigitte Dreno, Mariaelena Capone, Paolo A. Ascierto, Ilja Demuth, Elisabeth Steinhagen-Thiessen, Anis Larbi, Bastian Schilling, Dirk Schadendorf, Jedd D. Wolchok, Christian U. Blank, Graham PawelecClaus Garbe, Benjamin Weide

Research output: Contribution to journalArticlepeer-review

Abstract

Human γδ T-cells possess regulatory and cytotoxic capabilities, and could potentially influence the efficacy of immunotherapies. We analysed the frequencies of peripheral γδ T-cells, including their most prominent subsets (Vδ1+ and Vδ2+ cells) and differentiation states in 109 melanoma patients and 109 healthy controls. We additionally analysed the impact of γδ T-cells on overall survival (OS) calculated from the first dose of ipilimumab in melanoma patients. Higher median frequencies of Vδ1+ cells and lower median frequencies of Vδ2+ cells were identified in patients compared to healthy subjects (Vδ1+: 30% versus 15%, Vδ2+: 39% versus 64%, both p 

Original languageEnglish
Pages (from-to)116-126
Number of pages11
JournalEuropean Journal of Cancer
Volume64
DOIs
Publication statusPublished - Sep 1 2016

Keywords

  • Biomarker
  • Immunotherapy
  • Ipilimumab
  • Melanoma
  • Survival
  • γδ T-cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab'. Together they form a unique fingerprint.

Cite this